Disitamabvedotin is a drug used to treat metastatic gastric cancer. It is an advanced monoclonal antibody drug that kills tumor cells by binding to and releasing cytotoxic substances on the surface of tumor cells. The following will provide a detailed introduction to the mechanism of action of vediximab and its application in the treatment of metastatic gastric cancer.
1. Mechanism of action
The mechanism of action of vediximab idexi is based on two key components: monoclonal antibodies and cell toxins. This monoclonal antibody achieves targeted therapy against tumor cells by specifically binding to the overexpressed cell secreted antigen (CEACAM5) on the surface of tumor cells. Once vediximab binds to the surface of tumor cells, it is taken up by the cells and releases cytotoxic substances.
2. The role of cytotoxins
Vidiximab binds to lysosomal proteins (MMAE) in tumor cells, which is a potent cytotoxic agent. Once MMAE is released into tumor cells, it interferes with the microtubule network of the cells, leading to impaired cell division and growth. Ultimately, the action of cytotoxins leads to the death of tumor cells.
3. Application in the treatment of metastatic gastric cancer
Vediximab and Adissib have shown significant efficacy in the treatment of metastatic gastric cancer. Clinical trials have shown that patients using vediximab and idexi have better survival and quality of life compared to traditional chemotherapy drugs. It can be used for patients who continue to progress after chemotherapy and other treatment methods, as well as for patients who are resistant to other treatment methods.
4. Adverse reactions and precautions
Although vediximab idexi has shown potential benefits in the treatment of metastatic gastric cancer, it may also cause some adverse reactions. Common adverse reactions include fatigue, nausea, vomiting, diarrhea, and loss of appetite. In addition, it may also lead to some more serious adverse reactions, such as peripheral neuropathy. Therefore, before using vediximab idexi, patients should discuss the potential benefits and risks in detail with their doctors and make individualized treatment decisions.
